Clinical Trial Detail

NCT ID NCT03875313
Title Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Calithera Biosciences, Inc
Indications

colorectal cancer

clear cell renal cell carcinoma

triple-receptor negative breast cancer

Therapies

Talazoparib + Telaglenastat

Age Groups: adult senior

No variant requirements are available.